Efficacy and Safety of Conversion Surgery for Advanced Hepatocellular Carcinoma After Hepatic Arterial Infusion Chemotherapy

• DOI: 10.2147/jhc.s447387
• Publication Date: 2024-03-04T06:15:07Z
• Authors: Wenxuan Li; Zhikai Zheng; Jiongliang Wang; Tianqing Wu; Juncheng Wang; Yangxun Pan; Jinbin Chen; Dandan Hu; Li Xu; Yaojun Zhang; Minshan Chen; Zhongguo Zhou
• Keywords: 03 medical and health sciences; 0302 clinical medicine; hepatic arterial infusion chemotherapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; advanced hepatocellular carcinoma; conversion therapy; Journal of Hepatocellular Carcinoma; RC254-282; Original Research

Purpose:The aim of this study was to investigate the efficacy and safety conversion surgery for advanced hepatocellular carcinoma (HCC) after hepatic arterial infusion chemotherapy (HAIC).Patients Methods: Data from 172 HCC patients treated at Sun Yat-sen University Cancer Center between January 2016 June 2021 with effective assessment HAIC treatment response were retrospectively analyzed.Clinical pathological data, process, survival, occurrence adverse events recorded.Patients grouped according whether they achieved imaging remission HAIC, underwent surgery, met surgical resection criteria.Efficacy analyzed.Results: The median progression-free survival (PFS) overall (OS) in group 8.6 months 26.3 months, respectively, which longer than 4.6 (P<0.05) 15.6 nonremission group.Compared 6.7 18.9 maintenance group, PFS OS 16.5 45.0 (P<0.05),but there a higher risk treatment-related hemoglobin decrease, alanine aminotransferase increase, aspartate total bilirubin increase (P<0.05).The biliary fistula, abdominal hemorrhage ascites that single (P<0.05).Compared who criteria shorter: 7.1 21.7 (P<0.05),respectively.All during less moderate, no toxicity-related deaths occurred follow-up.Conclusion: HAIC-based therapy had acceptable toxic effects could effectively stabilize intrahepatic lesions HCC, improve benefit patients, provide some opportunity further prognosis.